For a 55-year-old patient on long-term escitalopram 20 mg who is now experiencing fatigue, low energy, and low motivation, is it appropriate to add bupropion (Wellbutrin) 75 mg and then increase to bupropion XL 150 mg?

Adding Bupropion to Long-Term Escitalopram for Fatigue and Low Motivation

Yes, adding bupropion 75 mg and titrating to 150 mg XL is an appropriate and evidence-based strategy for this patient experiencing fatigue, low energy, and low motivation on long-term escitalopram 20 mg. This represents a well-established augmentation approach for residual depressive symptoms, particularly those involving energy and motivation.

Rationale for Bupropion Augmentation

The combination of escitalopram and bupropion targets complementary neurotransmitter systems—escitalopram enhances serotonergic activity while bupropion increases dopaminergic and noradrenergic transmission 1, 2. This mechanistic difference makes bupropion particularly effective for residual symptoms of hypersomnia, fatigue, low energy, and decreased motivation that often persist despite adequate SSRI treatment 3, 4.

Evidence Supporting This Approach

Guideline-level support: Multiple clinical practice guidelines explicitly recommend bupropion augmentation for patients with incomplete response to SSRIs. The 2016 AACE/ACE guidelines note bupropion's "activating" properties and "possible rapid improvement of energy level" 1. The 2010 NCCN cancer pain guidelines list bupropion starting at 100-150 mg daily, increasing to 150-450 mg daily for neuropathic pain augmentation 2, demonstrating its established role as an adjunctive agent.

Research evidence: A 2018 double-blind randomized trial found that escitalopram-bupropion combination therapy achieved significantly faster onset of remission (at week 2) compared to either monotherapy, with sustained benefits through 12 weeks and 6-month maintenance 5. A 2004 naturalistic study comparing combination versus switching strategies found the combination approach superior, with 28% remission rate versus 7% for monotherapy switch (p<0.05) 6. Importantly, a 2014 pooled analysis of six trials demonstrated that bupropion-treated patients who achieved remission had significantly fewer residual symptoms of sleepiness (18.9% vs 32.1%, p<0.01) and fatigue (19.5% vs 30.2%, p<0.05) compared to SSRI-treated remitters 3.

Dosing Strategy

Recommended Titration Schedule

Start with bupropion SR 100-150 mg once daily in the morning (not the 75 mg you mentioned, as this is below standard starting doses) 1, 2, 7:

• Week 1-3: Bupropion SR 150 mg once daily in morning
• Week 4+: Increase to bupropion XL 150 mg once daily if tolerated
• Week 8+: Consider increasing to 300 mg daily if response is incomplete (maximum 450 mg/day) 7

Continue escitalopram 20 mg throughout this process. The FDA label for bupropion (Wellbutrin) specifies gradual dose escalation to minimize seizure risk, with increases every 3-5 days for immediate-release formulations or weekly for extended-release 7.

Timing Considerations

• Give the second dose before 3 PM to minimize insomnia risk 1
• Assess response at 4-8 weeks, as full therapeutic benefit requires this duration 1, 5
• If using twice-daily dosing, avoid late afternoon/evening administration 8

Safety Monitoring

Key Contraindications and Precautions

Absolute contraindications 7:

• Seizure disorder or conditions increasing seizure risk (severe head injury, CNS tumor, stroke)
• Eating disorders (anorexia nervosa, bulimia)
• Abrupt discontinuation of alcohol, benzodiazepines, or barbiturates
• Current MAOI use (within 14 days)

Relative cautions 7, 9:

• Monitor blood pressure regularly—bupropion can cause hypertension (check baseline and periodically)
• Watch for neuropsychiatric symptoms: agitation, anxiety, mood changes, suicidal ideation (especially first 4-8 weeks)
• Assess for seizure risk factors: diabetes on insulin, excessive alcohol use, concomitant medications lowering seizure threshold

Common Side Effects

The combination is generally well-tolerated. In the 2008 open-label study, only 6% discontinued due to side effects 10. The most common adverse effects include:

• Insomnia (4%)—mitigated by morning dosing
• Dry mouth (20%)
• Nausea—less common than with SSRIs alone
• Anxiety/agitation—monitor closely, especially initially 7

Important advantage: Unlike SSRIs, bupropion does not cause sexual dysfunction and may actually improve SSRI-induced sexual side effects 11, 12. In one study comparing escitalopram to bupropion, orgasm disorder (p=0.018) and sexual dysfunction (p<0.001) were significantly more common with escitalopram 12.

Clinical Pearls and Pitfalls

When This Strategy Works Best

This patient's presentation—fatigue, low energy, and low motivation on adequate SSRI therapy—represents the ideal clinical scenario for bupropion augmentation. A 2025 analysis using machine learning identified that bupropion is most effective for hypersomnia, increased weight, increased appetite, or fatigue, while other antidepressants are preferable for insomnia or decreased appetite 4.

Common Pitfalls to Avoid

1. Don't start too low: The 75 mg dose you mentioned is subtherapeutic. Start at 150 mg SR or XL 1, 7

2. Don't expect immediate results: While some energy improvement may occur within 2 weeks 5, full assessment requires 4-8 weeks 1

3. Don't overlook seizure risk: The incidence is dose-dependent (0.1% at ≤300 mg/day, nearly 1% at 450 mg/day) 7. Never exceed 450 mg/day total, and avoid in patients with seizure risk factors

4. Don't discontinue abruptly: If stopping bupropion after prolonged use, taper over at least 1 week to avoid withdrawal symptoms 13, 7

5. Monitor for activation: While beneficial for energy, excessive activation can manifest as anxiety, agitation, or insomnia—adjust timing or dose accordingly 1, 7

Alternative Consideration

If augmentation fails after 12 weeks at adequate doses, consider switching strategies rather than continuing ineffective treatment 14, 15. However, the evidence favors augmentation over switching in this scenario 6.

Expected Outcomes

Based on the research evidence, you can expect:

• Early response (2 weeks): Possible improvement in energy and motivation 5
• 12-week outcomes: 50-62% response rate, 39-50% remission rate 10, 6
• Long-term maintenance: Low relapse rates when continued 5

The combination of escitalopram and bupropion is superior to either monotherapy for achieving and maintaining remission in patients with residual depressive symptoms, particularly those involving energy, motivation, and fatigue 5, 6, 3.